AU2009221722B2 - Oxadiazoanthracene compounds for the treatment of diabetes - Google Patents

Oxadiazoanthracene compounds for the treatment of diabetes Download PDF

Info

Publication number
AU2009221722B2
AU2009221722B2 AU2009221722A AU2009221722A AU2009221722B2 AU 2009221722 B2 AU2009221722 B2 AU 2009221722B2 AU 2009221722 A AU2009221722 A AU 2009221722A AU 2009221722 A AU2009221722 A AU 2009221722A AU 2009221722 B2 AU2009221722 B2 AU 2009221722B2
Authority
AU
Australia
Prior art keywords
phenyl
oxo
diaza
hexahydro
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009221722A
Other languages
English (en)
Other versions
AU2009221722A1 (en
Inventor
Christopher Behme
Stephen Thomas Davis
Mustafa Guzel
Santhosh Chidambareswaran Kalpathy
Adnan M. M. Mjalli
Dharma Rao Polisetti
Thomas Scott Yokum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of AU2009221722A1 publication Critical patent/AU2009221722A1/en
Assigned to TRANSTECH PHARMA, LLC. reassignment TRANSTECH PHARMA, LLC. Request for Assignment Assignors: TRANSTECH PHARMA, INC.
Application granted granted Critical
Publication of AU2009221722B2 publication Critical patent/AU2009221722B2/en
Assigned to VTV THERAPEUTICS LLC reassignment VTV THERAPEUTICS LLC Request to Amend Deed and Register Assignors: TRANSTECH PHARMA, LLC.
Assigned to VTV THERAPEUTICS LLC reassignment VTV THERAPEUTICS LLC Request for Assignment Assignors: VTV THERAPEUTICS LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2009221722A 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes Active AU2009221722B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
US61/034,599 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (2)

Publication Number Publication Date
AU2009221722A1 AU2009221722A1 (en) 2009-09-11
AU2009221722B2 true AU2009221722B2 (en) 2014-12-18

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009221722A Active AU2009221722B2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Country Status (17)

Country Link
US (7) US7727983B2 (https=)
EP (1) EP2262364B1 (https=)
JP (1) JP5382952B2 (https=)
KR (1) KR101616737B1 (https=)
CN (1) CN101959405B (https=)
AU (1) AU2009221722B2 (https=)
BR (1) BRPI0910282A2 (https=)
CA (1) CA2716664C (https=)
DK (1) DK2262364T3 (https=)
EA (1) EA018225B1 (https=)
ES (1) ES2567451T3 (https=)
IL (1) IL207570A (https=)
MA (1) MA32175B1 (https=)
MX (1) MX2010009752A (https=)
NZ (1) NZ587343A (https=)
WO (1) WO2009111700A2 (https=)
ZA (1) ZA201006367B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727983B2 (en) 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) * 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
WO2012096824A1 (en) 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
HRP20161177T1 (hr) 2011-02-08 2016-11-04 Pfizer Inc. Modulator glukagonskog receptora
AU2012288493B2 (en) 2011-07-22 2015-08-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
SG10201704716XA (en) * 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
EP3172199B1 (en) * 2014-07-25 2020-07-01 Celgene International II Sarl Pyrimidine derivatives as glp-1 receptor modulators
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物
EP3790549A1 (en) 2018-05-08 2021-03-17 vTv Therapeutics LLC Therapeutic uses of glp1r agonists
CR20210341A (es) 2018-11-22 2021-11-25 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
US20230348484A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist free base
EP4159719A4 (en) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
AU2021306414B2 (en) 2020-09-01 2026-01-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4227299A4 (en) 2020-10-12 2025-04-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE
TWI912388B (zh) * 2020-10-14 2026-01-21 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ-１ｒ促效劑的晶型及其用途
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
WO2022268152A1 (zh) 2021-06-24 2022-12-29 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法
US20260097037A1 (en) 2022-09-22 2026-04-09 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789675A (en) * 1986-02-11 1988-12-06 Takeda Chemical Industries, Ltd. 1,4-benzoxazine derivatives and pharmaceutical use
US20040019072A1 (en) * 1995-10-06 2004-01-29 Stacie Canan-Koch Dimer-selective RXR modulators and methods for their use
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
EP1236719A4 (en) * 1999-12-03 2003-06-25 Kyoto Pharma Ind NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF, USE OF THESE COMPOUNDS IN MEDICINE
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
US7727983B2 (en) * 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789675A (en) * 1986-02-11 1988-12-06 Takeda Chemical Industries, Ltd. 1,4-benzoxazine derivatives and pharmaceutical use
US20040019072A1 (en) * 1995-10-06 2004-01-29 Stacie Canan-Koch Dimer-selective RXR modulators and methods for their use
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists

Also Published As

Publication number Publication date
ES2567451T3 (es) 2016-04-22
EP2262364B1 (en) 2016-03-02
US8524708B2 (en) 2013-09-03
EP2262364A2 (en) 2010-12-22
US8703766B2 (en) 2014-04-22
US20150087640A1 (en) 2015-03-26
US9120813B2 (en) 2015-09-01
IL207570A0 (en) 2010-12-30
EA018225B1 (ru) 2013-06-28
IL207570A (en) 2014-03-31
CA2716664C (en) 2016-10-11
CN101959405B (zh) 2014-07-02
JP5382952B2 (ja) 2014-01-08
EP2262364A4 (en) 2012-04-04
US20100197677A1 (en) 2010-08-05
NZ587343A (en) 2012-05-25
JP2011513431A (ja) 2011-04-28
US20100324033A1 (en) 2010-12-23
EA201071045A1 (ru) 2011-02-28
US20130317015A1 (en) 2013-11-28
WO2009111700A2 (en) 2009-09-11
MX2010009752A (es) 2010-09-30
US20110039837A1 (en) 2011-02-17
KR101616737B1 (ko) 2016-05-02
ZA201006367B (en) 2011-05-25
DK2262364T3 (en) 2016-03-21
US7727983B2 (en) 2010-06-01
CN101959405A (zh) 2011-01-26
CA2716664A1 (en) 2009-09-11
US20140187769A1 (en) 2014-07-03
WO2009111700A3 (en) 2010-03-04
MA32175B1 (fr) 2011-03-01
BRPI0910282A2 (pt) 2015-09-01
US8933222B2 (en) 2015-01-13
KR20100131455A (ko) 2010-12-15
HK1148435A1 (en) 2011-09-09
US7790714B2 (en) 2010-09-07
US7906507B2 (en) 2011-03-15
US20090306063A1 (en) 2009-12-10
AU2009221722A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
AU2009221722B2 (en) Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
HK1148435B (en) Oxadiazoanthracene compounds for the treatment of diabetes
CN118908937A (zh) 一种具有sting蛋白降解作用的化合物及其制备方法和用途
HK1164050B (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TRANSTECH PHARMA, LLC.

Free format text: FORMER APPLICANT(S): TRANSTECH PHARMA, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GUZEL, MUSTAFA; DAVIS, STEPHEN THOMAS; YOKUM, THOMAS SCOTT; MJALLI, ADNAN M. M.; KALPATHY,SANTHOSH CHIDAMBARESWARAN; BEHME, CHRISTOPHER AND POLISETTI, DHARMA RAO

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VTV THERAPEUTICS LLC

Free format text: FORMER OWNER WAS: VTV THERAPEUTICS LLC